Tepezza

Chemical Nameteprotumumab-trbw
Dosage FormInjection (intravenous; 500 mg/vial)
Drug ClassMonoclonal antibodies
SystemEndocrine
CompanyHorizon Therapeutics
Approval Year2020

Indication

  • For the treatment of Thyroid Eye Disease
Last updated on 3/24/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tepezza (teprotumumab-trbw) Prescribing Information.2020Horizon Therapeutics USA Inc., Lake Forest, IL